In March 2024 Transgene, NEC Corporation, and BostonGene Corporation announced the expansion of their collaboration for the randomised Phase I/II trial of TG4050. TG4050 is an investigational cancer therapy vaccine, individualised for patients with head and neck cancers. It is based on Transgene’s myvac platform and is powered by NEC’s AI-driven Neoantigen Prediction System. The partnership will continue to perform tumour molecular profiling and microenvironment analysis, providing high-throughput sequencing services.
TG4050
TG4050 is a virus-based individualised immunotherapy that encodes neoantigens identified and selected by the Neoantigen Prediction System. It is designed to “stimulate the immune system” to induce a T-cell response that can “recognise and destroy tumour cells based on their own neoantigens”.
Comments on the collaboration
Dr Alessandro Riva, Chair and CEO of Transgene, is pleased to continue the collaboration, which has provided “in-depth information on patient phenotypes in the Phase I trial”.
“It has allowed us to understand the baseline status of our patients and how the tumour micro-environment (TME) might evolve following treatment.”
Masamitsu Kitase, Corporate SVP and Head of the Healthcare and Life Sciences Division at NEC Corporation, commented on the “combined expertise” of the partnership, which will “continue to provide a streamlined pipeline”. This will ensure “timely delivery of patient-tailored vaccines” alongside “data to guide the future development of new personalised treatment options” with the goal of “elevating the standard of care for head and neck cancer patients”.
BostonGene’s Chief Medical Officer Dr Nathan Fowler is “committed to supporting Transgene and NEC as they advance these clinical trials”.
“Our molecular and immune profiling techniques comprehensively analyse the tumour, microenvironment, and immune system to identify key predictors of response to TG4050, ultimately improving treatment outcomes.”
For more on efforts to use revolutionary technology against various kinds of cancer, get your tickets to join us at the Congress in Washington this April or subscribe for our newsletters here.
